Amgen’s $28.3 billion acquisition of Horizon Therapeutics won’t go through without a hefty review from U.S. antitrust watchdogs. Tuesday, the companies revealed that they have received a second request for information from the Federal Trade Commission (FTC) as the agency scrutinizes the deal. Amgen and Horizon intend to promptly respond to the request, Horizon said […]
Physicians working in an outpatient setting, whether that’s an office-based lab (OBL) or ambulatory surgery center (ASC), face increasing scrutiny over whether the procedures they perform are done with the patients’ best interests in mind. Here at ISET 2023, one lawyer described the legal landscape, with advice on how to avoid getting embroiled in trouble.
As Outpatient Facilities Proliferate, So Too Does Scrutiny Read More »
The Federal Trade Commission (FTC) will reportedly not challenge UnitedHealth Group’s (NYSE: UNH) deal for LHC Group Inc. (Nasdaq: LHCG) after all. Both companies stock rose Tuesday after that news surfaced from a CTFN report. Just last week, LHC Group stock dropped after a report from Capitol Forum suggested that the FTC may be looking
FTC Unlikely to Challenge UnitedHealth Group-LHC Group Deal Read More »
The Biden administration late Monday announced the public health emergency (PHE) will officially end on May 11. The PHE has, in many ways, changed the game for behavioral health operators over the past three years. Among its impacts, it relaxed several regulations while notably expanding telehealth and medication-assisted treatment (MAT) access. Although the end of
Abipartisan state Senate bill would require health-care systems to submit acquisition and merger proposals for state attorney general review before reaching any agreement. Senate Bill 16, titled “Preserving Competition and Health Care,” was filed Wednesday. Mark Hall, a professor of Law and Public Health at Wake Forest University, said SB16 “aims to give the attorney
NC Senate Bill Would Give Attorney General More Oversight Over Health-Care System Deals Read More »
On January 5, 2023, the Federal Trade Commission (FTC) issued a proposed rule that would prohibit employers from using noncompete agreements with their employees or independent contractors. Noncompete agreements are prevalent in the physician practice industry, as stakeholders have long recognized the importance of noncompetes as a tool for physician alignment. Physician employers, such as
Sen. Elizabeth Warren (D-MA) is calling on senior Federal Trade Commission officials to “closely scrutinize” two proposed pharma mergers. Warren expressed concern over “rampant consolidation in the pharmaceutical industry,” in particular Amgen’s $28 billion plans to take over Horizon Therapeutics, and Indivior’s proposed acquisition of Opiant for $145 million upfront, in a letter to FTC
Sen. Elizabeth Warren Urges FTC to ‘Scrutinize’ Two Pharma Buyouts Read More »
LHC Group Inc. (Nasdaq: LHCG) had dropped close to 3.5% by market close on Thursday after a report suggested that the Federal Trade Commission (FTC) is reviewing its pending deal with UnitedHealth Group (NYSE: UNH) again, this time due to a potential vertical harm theory. Broadly, vertical harm theory concerns generally are tied to market
LHC Group-UnitedHealth Group Deal Hits Another Roadbump Read More »
Minnesota Attorney General Keith Ellison has asked for Sanford and Fairview to slow down their proposed mega-merger, saying a scheduled closing for the transaction on March 31 is coming too soon to address questions about the deal. Deputy Attorney General John Keller disclosed the request Wednesday night during a public meeting in Worthington. Keller cited
Minnesota Attorney General Calls for Delay in Sanford-Fairview Merger Timeline Read More »
The Biden administration is planning to release three to four new payment models on advance primary care and another enabling states to assume the total cost of care for Medicare, a top official shared. Center for Medicare and Medicaid Innovation (CMMI) Director Liz Fowler, Ph.D., detailed the center’s plans for this year during the Value-Based
